Moderna (NASDAQ:MRNA) Shares Up 1.2% – Here’s Why

Moderna, Inc. (NASDAQ:MRNA) shares rose 1.2% during mid-day trading on Tuesday. The stock traded as high as $218.48 and last traded at $216.25. 13,355,521 shares were traded during trading, an increase of 9% from the average daily volume of 12,250,907 shares. The stock had previously closed at $213.74.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Reports of encouraging results for Moderna’s personalized mRNA cancer vaccine have fueled optimism that oncology could become a major long-term growth driver. A planned NIH-backed initiative to accelerate personalized cancer-vaccine development is providing an additional industry catalyst. Moderna Cancer Vaccine Breakthrough
• Positive Sentiment: Moderna’s Nasdaq-100 inclusion has likely generated index-related buying and increased visibility among institutional investors, helping extend the recent rally. MRNA Stock Gains Over $4 Billion
• Positive Sentiment: Health Canada is reviewing Moderna’s next-generation mRNA flu vaccine, which could reduce hospitalizations if approved and give the company another potential growth opportunity beyond COVID-19 and cancer treatments. Health Canada Flu Vaccine Review
• Neutral Sentiment: Moderna will report third-quarter 2026 results on November 6, giving investors a forthcoming catalyst for evaluating revenue trends, cash usage, and progress on its pipeline. Moderna Third-Quarter 2026 Results
• Negative Sentiment: The rapid rally has prompted profit-taking and renewed concern that much of the cancer-vaccine and Nasdaq-100 news is already reflected in the stock’s valuation. Older analyst price targets cited by Quiver Quantitative are substantially below the current market level, underscoring downside risk if expectations weaken.
• Negative Sentiment: Reported open-market activity shows Moderna insiders made no purchases and sold shares during the past six months. That selling may reinforce investor caution after the stock’s sharp advance.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of analyst reports. Barclays boosted their price target on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research note on Monday, August 24th. Bank of America increased their price objective on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday. Evercore increased their price objective on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Bradesco Corretora raised shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a report on Friday, August 28th. They issued a “hold” rating and a $125.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $100.60.

Moderna Stock Up 1.2%

The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $143.25 and a two-hundred day moving average of $86.30. The firm has a market capitalization of $86.34 billion, a price-to-earnings ratio of -27.07 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.13) earnings per share. As a group, sell-side analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,281 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $146.07, for a total transaction of $5,883,845.67. Following the sale, the president directly owned 1,562,029 shares in the company, valued at $228,165,576.03. The trade was a 2.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 118,882 shares of company stock valued at $16,862,280. 10.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Sivik Global Healthcare LLC acquired a new position in Moderna in the third quarter valued at $1,926,000. NorthCrest Asset Manangement LLC bought a new position in Moderna in the third quarter worth approximately $234,000. Gallagher Capital Advisors LLC bought a new position in shares of Moderna in the 3rd quarter worth $2,244,000. Wedmont Private Capital grew its holdings in shares of Moderna by 55.4% during the third quarter. Wedmont Private Capital now owns 5,938 shares of the company’s stock valued at $1,170,000 after buying an additional 2,116 shares during the last quarter. Finally, Breakwater Capital Group acquired a new position in Moderna during the 3rd quarter valued at about $304,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.